Key terms
About EXAS
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EXAS news
Apr 29
11:29am ET
Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
Apr 25
4:45pm ET
Exact Sciences Announces Board Member Retirement
Apr 15
10:21am ET
Exact Sciences CFO’s resume ‘impressive,’ says William Blair
Apr 15
6:32am ET
Exact Sciences Appoints Aaron Bloomer as New CFO
Apr 15
6:02am ET
Exact Sciences names Aaron Bloomer as CFO, effective May 15
Apr 09
9:00pm ET
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
Apr 04
6:09am ET
Exact Sciences to supply individual cancer information to Mayo Clinic patients
Apr 03
8:21am ET
Exact Sciences removed from ‘Tactical Outperform’ list at Evercore ISI
Apr 03
6:03am ET
Citi opens ‘positive catalyst watch’ on Exact Sciences after competitor data
Apr 03
5:19am ET
Canaccord positive on Exact, Guardant after Freenome data
Apr 02
9:49am ET
Exact Sciences, Guardant rally after Freenome colorectal cancer test results
Apr 02
9:41am ET
Unusually active option classes on open April 2nd
Mar 28
6:09am ET
Exact Sciences’ Oncoguard Esophagus test shows efficacy in published study
Mar 21
11:06am ET
EXACT Sciences call volume above normal and directionally bullish
Mar 19
8:31am ET
Exact Sciences added to ‘Tactical Outperform’ list at Evercore ISI
Mar 19
2:40am ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Mar 13
5:04pm ET
Exact Sciences says Cologuard Plus test results published in NEJM
Feb 27
5:25am ET
Exact Sciences (EXAS) Receives a Buy from BTIG
Feb 26
8:00am ET
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
Feb 26
12:01am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), Teleflex (TFX) and Amgen (AMGN)
Feb 25
11:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Feb 22
8:34am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Moderna (MRNA) and Glaukos (GKOS)
Feb 22
8:10am ET
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Exact Sciences (EXAS) and DarioHealth (DRIO)
Feb 22
8:05am ET
Piper Sandler Sticks to Their Buy Rating for Exact Sciences (EXAS)
Feb 22
7:32am ET
Exact Sciences price target lowered to $90 from $100 at Canaccord
Feb 22
7:25am ET
Exact Sciences price target lowered to $85 from $90 at BTIG
Feb 22
7:04am ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)
Feb 22
5:50am ET
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN) and Exact Sciences (EXAS)
Feb 22
12:00am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 21
11:50pm ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Tandem Diabetes Care (TNDM)
Feb 21
10:46pm ET
Buy Rating Affirmed for Exact Sciences on Strong Quarterly Performance and Growth Potential
No recent press releases are available for EXAS
EXAS Financials
Key terms
Ad Feedback
EXAS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EXAS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range